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TO THE EDITOR
We read with great interest the original
article by Wang et al. (2013) published
in this journal.
The authors investigated the effects
of proinflammatory cytokines (i.e., TNF
and IL-17) on epidermal melanocytes
and their contribution to postinflamma-
tory hyperpigmentation in psoriatic
patients.
They demonstrated that primary
human melanocytes respond to IL-17
and/or TNF stimulation forming clusters
and modulating the expression of a
broad panel of genes. In particular,
synergistic stimulation of melanocytes
with IL-17 and TNF leads to increased
expression of mitogenic cytokines and
growth factor genes (e.g., CXCL-1 and
IL-8) and downregulates the pigmenta-
tion signaling pathway and melanin
production (e.g., c-Kit, MC1R, Mitf,
Dct). There is also a significant decrease
of tyrosinase levels and cellular melanin
content.
Moreover, given the pathogenic role
of TNF and IL-17 in psoriasis, Wang
et al. investigated the pigmentation genes
in psoriatic plaques and, as expected,
they found a broad inhibition of genes
involved in melanin synthesis, catalytic
enzymes, and lineage-specific melano-
cyte transcriptional factors. Indeed,
they found overexpression of a MC1R
keratinocyte–derived antagonist (i.e.,
beta defensin 3) in psoriatic plaques.
Taken together, all these findings
suggest that the psoriatic inflammatory
milieu exerts a protective role against
melanogenesis. Recently, we (Di Cesare
et al., 2013) and others (Balato et al.,
2011) reported that psoriatic patients
have a low number of melanocytic
nevi as compared with healthy controls.
Indeed, we found that the probability of
having melanocytic nevi in psoriatic
patients was 82% lower compared with
controls even independently of personal
and medical confounders such as socio-
demographic factors, skin type and
acute and/or chronic sun exposure,
family history of cancer, and psoriasis-
associated factors, such as disease family
history, obesity, metabolic syndrome,
cigarette smoking, and alcohol consump-
tion (Di Cesare et al., 2013).
In their paper, Wang et al. (2013) also
demonstrated that psoriatic skin has an
increased number of melanocytes, with
a positive MelanA staining. They
reported that psoriatic lesional skin,
and not nonlesional or healthy control
skin, is Ki67þ /MART-1þ . This means
that, despite IL-17/TNF brake on
melanogenesis, melanocytes do not
migrate from the inflamed skin to IL-17/
TNF-free areas, but conversely they still
infiltrate the plaques, expressing CCL20
and other adhesion molecules (Wang
et al., 2013). Therapeutic neutralization
of IL-17 and TNF with biologic agents is
able to recover pigmentation signaling,
leading to postinflammatory hyper-
pigmentation in the areas correspon-
ding to the plaques that were enriched
with melanocytes. In our opinion, this is
a clue point to elucidate the mechanism
of posttherapeutic development of lenti-
gines confined to the areas of pre-
existing psoriatic plaques that has been
reported following phototherapy, topical
treatments, or biologic agents (Burrows
et al., 1994; Ana Costa et al., 2009;
Santos-Juanes et al., 2008; Martı` et al.,
2009; Bardazzi et al., 2012).
We observed the appearance of
speckled hyperpigmentation within the
psoriatic plaque areas during treatment
with biologics in six patients (2 F, 4 M;
median age: 64 years; range: 50–75
years) during the treatment with adalimu-
mab (3/6) (Figure 1), infliximab (1/6),
ustekinumab (1/6), and etanercept (1/6)
(Figure 2). A written consent for skin
biopsies and photographic documenta-
tion was obtained for each patient. All
patients were affected with moderate-
to-severe psoriasis (psoriasis area and
severity index410) and 5/6 had conco-
mitant psoriatic arthritis; 4/6 patients had
o10 nevi, and 2/6 had a total number of
nevi between 10 and 30. All patients had
received several cycles of topical (corti-
costeroids and/or vitamin D analogue,
retinoids) and systemic treatments includ-
ing ciclosporin (5/6), methotrexate (3/6),Accepted article preview online 18 July 2014; published online 21 August 2014
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and retinoids (1/6). Notably, the lentigines
at the sites of psoriatic plaques occurred
exclusively after treatment with biologics,
and they were persistent after treatment
discontinuation or after a second course
of treatment with the same biologic or
even with a biologic of different class.
We also observed that switching from
etanercept to adalimumab or prolonged
Figure 1. Progressive development of diffuse speckled lentiginoses in a psoriatic patient treated with anti-tumor necrosis factor-a agents. (a) Patient at baseline
(psoriasis area and severity index (PASI) 30). (b) Week 12 of treatment with etanercept s.c. 100 mg per week (PASI 10.2). (c) Week 36 of treatment with etanercept
s.c. 50 mg per week (PASI 16.7). Development of speckled lentiginoses in the resolving areas of psoriasis following the reduction of the erythema. Loss of clinical
efficacy and switch to adalimumab. (d) Long-term treatment with adalimumab (over 4 years): complete clearance of psoriasis and evident stable lentiginoses,
diffused over the body areas that were previously covered by psoriatic plaques.
Figure 2. Posttherapeutic speckled lentiginoses at the sites of previous psoriatic plaques. (a) Patient at baseline (psoriasis area and severity index 29.6).
(b) Development and progressive darkening of speckled hyperpigmented patches after 48 weeks and (c) over 3 years of long-term treatment with adalimumab.
(d) Lentigine development in sun-protected areas as early as week 24 of treatment with etanercept. (e) Histopathological examination of a lentiginous patch,
in a patient treated with adalimumab, shows hyperpigmentation of basal cells of the skin (hematoxylin–eosin stain; original magnification  10).
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treatments can lead to strong hyperpig-
mentation (Figures 1 and 2).
According to previous reports (Ana
Costa et al., 2009; Bardazzi et al.,
2012), we observed that the clinical
aspect of lentiginous patches histo-
logically correspond to basal cell
hyperpigmentation and elongation of
the rete ridges (Figure 2), with slightly
increased number of normal melano-
cytes at the dermo-epidermal junction
(Melan A staining, data not shown).
Therefore, on the basis of the findings
of Wang et al., and our observations, we
hypothesize that biologic-mediated
removal of the IL-17/TNF brake activates
locally infiltrated melanocytes, which
are increased in number in psoriatic skin
versus perilesional and/or normal skin,
to produce melanin, to form clusters,
and to express adhesion molecules. This
phenomenon leads either to transitory
postinflammatory hyperpigmentation or
to stable lentiginosis, as observed in our
patients.
In addition, the findings of Wang
et al. also support the idea of a role for
melanocytes infiltrating the plaques
in sunlight-mediated pigmentation.
The increased number of melanocytes
in psoriatic plaques might somehow
explain the lower tendency to be
affected by sunburns displayed by psor-
iatic patients versus controls (Di Cesare
et al., 2013), although the exact mech-
anisms linking sun exposure, sunburns,
tanning, and nevi/melanoma develop-
ment are still not clearly understood,
and they have been linked to the direct
effects of UV light on both melano-
cytes and the immune system, via the
RAS/RAF/MAPK pathway and/or p53
involvement (Heck et al., 2004; Cui
et al., 2007; Kannengiesser et al.,
2008; Bataille, 2013).
The data of Wang et al. raise another
important point of discussion. Interest-
ingly, we found that biologic– and not
UV phototherapy–treated patients have
35% more nevi than patients naive to
biologics (Di Cesare et al., 2013). All
(140/141 patients; 99.3%) but one (who
received an anti-IL-12/23p40 agent) of
our patients were exposed to at least
one cycle of anti-TNFa therapy. Pre-
vious in vitro research (Ortega et al.,
2009) showed that treatment with the
anti-TNF-mAb significantly reduces
IL-17 production. Taken together, these
data support our hypothesis that selec-
tive interference of TNF and/or IL-17
in psoriasis can result in melanocyte
activation.
However, this phenomenon seems to
be confined to the development of
benign melanocytic lesions and
does not result in an increased risk of
malignant lesions. We observed no
cases of melanoma during biologic
treatment, and there are only anecdotic
cases of melanoma in psoriasis in the
literature (Kowalzick et al., 2009;
Marasini et al., 2011). Indeed,
melanoma development is a multi-
factorial event, as it is linked to genetic
and environmental factors (e.g., UV
exposure) (Regad, 2013). The use
of anti-TNFa biologic agents mainly
leads to physiological events, reach-
ing homeostasis between biologics
and TNF/IL-17 activity, confirmed by
the short- and long-term safety data
(Rustin, 2012) and by removing the
brake on proliferation but not on cell
cycle/pro-oncogenic genes.
In conclusion, our findings are per-
fectly in line with the hypothesis that a
high amount of TNF and IL-17 acts as a
brake on melanogenesis and that releas-
ing the brake via the use of anti-TNFa
or anti-IL-17 agents can locally activate
melanocytes.
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